

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

INSIDE INFORMATION POSSIBLE ACQUISITIONS

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POSSIBLE ACQUISITIONS

The board of directors of the Company announces that the Group is in a preliminary stage of considering the feasibility of possible acquisitions (the “**Possible Acquisitions**”) of equity interest in companies in Northern region in the People’s Republic of China principally engaged in distribution of medical devices including in-vitro diagnostic products (the “**Target Companies**”) from third parties independent from the Group or its connected persons (as defined under the Listing Rules).

The Group is carrying out due diligence review on the Target Companies. As at the date of this announcement, no definitive legally binding agreement or undertaking has been entered into by the Group. The Possible Acquisitions are subject to, among other conditions, further negotiation and the results of the due diligence, which may or may not materialize. If any Possible Acquisition materializes, the Possible Acquisition is expected to constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

Further detailed announcement(s) will be made by the Company in compliance with the requirements of the Listing Rules as and when appropriate, should there be any material development in connection with the Possible Acquisitions.

Shareholders of the Company and potential investors should note that the Possible Acquisitions may or may not materialize. Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

Hong Kong, 14 August 2017

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong and Mr. Chan Chung Man; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.